In this Roklen24 interview, co-founder Michal Zahradníček discusses how Europe often struggles to translate research into commercial success—many innovators head to the U.S. LIFE BioCEEd addresses this gap by investing in high-impact medical technologies and applying its multi-disciplinary know-how for successful tech transfer. Collaborating with universities and research centers across CEE, the company targets breakthrough inventions beyond traditional pharmaceuticals, guiding them from patent to profitable product.

Read the full interview here:

https://roklen24.cz/investicni-spolecnost-life-bioceed-chce-menit-medicinske-patenty-v-technologie-investuje-do-nich-pul-miliardy-korun/